Date and duration
Date: March 16th
Time: 9am GMT
Duration: 45 minutes
Virtual screening can be a very efficient way to identify initial lead molecules or a back-up series for a drug discovery program. Obvious advantages include access to increased molecular diversity, an ability to find new IP, savings in time and ultimately cost. One of the most critical challenges of virtual screening is determining the most effective screening strategy: this implies working through the data and detail of the experimental design to achieve the desired outcome for any given starting point.
In this webinar we will show how Flare™, Forge™ and Blaze™ can be used to analyze and develop an appropriate virtual screening strategy for complex target systems for which no simple small ligands exists, and how that can be worked into an effective virtual screen.
About the presenter
Dr Martin Slater studied medicinal chemistry at the Universities of Leeds and Huddersfield. In 1997 he joined the then start-up company BioFocus where, as Senior Research Fellow, he underpinned the SoftFocus library brand with the development of innovative chemogenomic tools and the design of over 40 commercially successful protein targeted libraries. Martin pioneered the use of Cresset’s field based technologies for targets including GPCRs, Kinases, Ion channels and Proteases for library generation and de-novo ligand design.
Martin joined Cresset in 2011 as Director of Consulting Services, delivering high quality computational chemistry and molecular modelling service to pharma, biotech, agrochem, academia, flavors and fragrances industries amongst others.